The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs

Neurology

Volumn 64, Issue 8, 2005, Pages 1397-1403

  Burns, J M ^a,c   Galvin, J E ^a,b   Roe, C M ^a,b   Morris, J C ^a,b   McKeel, D W ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; COG WHEEL PHENOMENON; NEUROLEPTIC AGENT; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRADYKINESIA; BRAIN NERVE CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GAIT DISORDER; HUMAN; MALE; MUSCLE RIGIDITY; NERVE CELL NECROSIS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; SUBSTANTIA NIGRA; TREMOR;

EID: 17644392127     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000158423.05224.7F     Document Type: Article

References (47)

1. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease: a role for extranigral factors? Arch Neurol 1989;46:651-657.
2. Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA. Progression of parkinsonism and loss of cognitive function in Alzheimer disease. Arch Neurol 2000;57:855-860.
3. Drachman DA, O'Donnell BF, Lew RA, Swearer JM. The prognosis in Alzheimer's disease. "How far" rather than "how fast" best predicts the course. Arch Neurol 1990;47:851-856.
4. Murman DL, Kuo SB, Powell MC, Colenda CC. The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology 2003;61:944-949.
5. Haan MN, Jagust WJ, Galasko D, Kaye J. Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease. Arch Neurol 2002;59:588-593.
6. Kazee AM, Cox C, Richfield EK. Substantia nigra lesions in Alzheimer disease and normal aging. Alzheimer Dis 1995;9:61-67.
7. Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 1997;41:368-374.
8. Gibb WR, Mountjoy CQ, Mann DM, Lees AJ. The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. J Neurol Neurosurg Psychiatry 1989;52:193-200.
9. Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology 1987;37:754-760.
10. Hulette C, Mirra S, Wilkinson W, Heyman A, Fillenbaum G, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part LX. A prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. Neurology 1995;45:1991-1995.
11. Joachim CL, Morris JH, Selkoe DJ. Clinically diagnosed Alzheimer's disease: autopsy results in 150 cases. Ann Neurol 1988;24:50-56.
12. Gibb WR, Esiri MM, Lees AJ. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987;110:1131-1153.
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
14. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathological entity. Neurology 1990;40:1-8.
15. Olichney JM, Galasko D, Salmon DP, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998;51:351-357.
16. Heyman A, Fillenbaum GG, Gearing M, et al. Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, part XIX. Neurology 1999;52:1839.
17. Rinne JO, Rummukainen J, Paljarvi L, Sako E, Molsa P, Rinne UK. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia. Prog Clin Biol Res 1989;317:325-332.
18. Ala TA, Yang KH, Sung JH, Frey WH. Inconsistency between severe substantia nigra degeneration with Lewy bodies and clinical parkinsonism in dementia patients: a cliniconeuropathological study. Acta Neuropathol 2000;99:511-516.
19. Ala TA, Yang KH, Sung JH, Frey WH. Clinical parkinsonism in dementia patients with substantia nigra Lewy bodies. J Neural Transm 1999;106:47-57.
20. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol 2001;58:397-405.
21. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
22. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
23. Berg L, Miller JP, Storandt M, et al. Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment. Ann Neurol 1988;23:477-484.
24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
25. Morris JC, McKeel DW, Fulling K, Torack RM, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol 1988;24:17-22.
26. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-335.
27. Davis PB, White H, Price JL, McKeel DW, Robins LN. Retrospective postmortem dementia assessment: validation of a new clinical interview to assist neuropathologic study. Arch Neurol 1991;48:613-617.
28. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-335.
29. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-548.
30. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76.
31. McKeel DW Jr, Ball MJ, Price JL, et al. Interlaboratory histopathologic assessment of Alzheimer neuropathology: different methodologies yield comparable diagnostic results. Alzheimer Dis 1993;7:136-151.
32. McKeel DW, Price JL, Miller JP, et al. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. J Neuropathol Exp Neurol (in press).
33. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996;47:1113-1124.
34. Mirra SS, Heyman A, McKeel DW, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
35. Hurtig HI, Trojanowski JQ, Galvin JE, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
36. Braak H, Tredici KD, Rub U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
37. Stern Y, Jacobs D, Goldman J, et al. An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol 2001;58:460-465.
38. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci 1993;16:460-465.
39. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer's disease. Neurology (in press).
40. Wilson RS, Bennett DA, Gilley DW, Beckett LA, Schneider JA, Evans DA. Progression of parkinsonism and loss of cognitive function in Alzheimer disease. Arch Neurol 2000;57:855-860.
41. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003;300:636-640.
42. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997;41:615-620.
43. Bales KR, Dodart JC, DeMattos RB, Holtzman DM, Paul SM. Apolipoprotein E, amyloid, and Alzheimer disease. Mol Interv 2002;2:363-375.
44. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-affinity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977-1981.
45. Ohm TG, Scharnagl H, Marz W, Bohl J. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol (Berl) 1999;98:273-280.
46. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E [epsi]4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol 1998;153:152-155.
47. Fahn S, Elton RL Upm. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.